3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
5
Active not recruiting
4
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
16
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Mantle-Cell
4
Lymphoma
4
Waldenstrom Macroglobulinemia
3
Recurrence
3
Neoplasms
3
Leukemia
2
Primary Central Nervous System Lymphoma (PCNSL)
1
Neuroectodermal Tumors, Primitive
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphatic Diseases
1
Leukemia, Lymphoid
1
Leukemia, Hairy Cell
1
Leukemia, B-Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Glioblastoma
1
Ependymoma
1
Burkitt Lymphoma
1
Bronchiolitis Obliterans Syndrome
1
Brain Neoplasms
1
Anemia, Hemolytic, Autoimmune
1
Interventions
Cyclophosphamide
7
acalabrutinib
4
pirtobrutinib
3
fludarabine
3
Rituximab
3
fludarabine phosphate
2
Vincristine
2
Melphalan
2
Doxorubicin
2
thymoglobulin
1
obinutuzumab
1
idecabtagene vicleucel
1
ibrutinib
1
Stem Cell Transplantation
1
Prednisone
1
Prednisolone
1
Mycophenolic Acid
1
Mesna
1
Immunotherapy, Adoptive
1
Filgrastim
1
Diet
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, B-Cell
×
ibrutinib
×
Clear all
NCT05254743
2026-04-20
BRUIN-CLL-314
Eli Lilly and Company
Phase 3
Recruiting
662 enrolled